159 related articles for article (PubMed ID: 36991394)
21. Implementation strategies for the introduction of the RTS,S/AS01 (RTS,S) malaria vaccine in countries with areas of highly seasonal transmission: workshop meeting report.
Merle CS;
Malar J; 2023 Aug; 22(1):242. PubMed ID: 37612716
[TBL] [Abstract][Full Text] [Related]
22. Factors associated with malaria vaccine uptake in Nsanje district, Malawi.
Simbeye AJ; Kumwenda S; Cohee LM; Omondi D; Masibo PK; Wao H; Awandu SS
Malar J; 2024 Apr; 23(1):105. PubMed ID: 38627704
[TBL] [Abstract][Full Text] [Related]
23. Acceptance, availability, and feasibility of RTS, S/AS01 malaria vaccine: A review.
Mumtaz H; Nadeem A; Bilal W; Ansar F; Saleem S; Khan QA; Tango T; Farkouh C; Belay NF; Verma R; Farkouh M; Saqib M
Immun Inflamm Dis; 2023 Jun; 11(6):e899. PubMed ID: 37382251
[TBL] [Abstract][Full Text] [Related]
24. Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa.
Leach A; Vekemans J; Lievens M; Ofori-Anyinam O; Cahill C; Owusu-Agyei S; Abdulla S; Macete E; Njuguna P; Savarese B; Loucq C; Ballou WR;
Malar J; 2011 Aug; 10():224. PubMed ID: 21816029
[TBL] [Abstract][Full Text] [Related]
25. Malaria vaccine coverage estimation using age-eligible populations and service user denominators in Kenya.
Moturi AK; Jalang'o R; Cherono A; Muchiri SK; Snow RW; Okiro EA
Malar J; 2023 Sep; 22(1):287. PubMed ID: 37759277
[TBL] [Abstract][Full Text] [Related]
26. Setting up a data system for monitoring malaria vaccine introduction readiness and uptake in 42 health districts in Cameroon.
Mboussou F; Ndoula ST; Nembot R; Baonga SF; Njinkeu A; Njoh AA; Biey JN; Kaba M; Amani A; Farham B; Habimana P; Impouma B
BMJ Glob Health; 2024 Apr; 9(4):. PubMed ID: 38580377
[TBL] [Abstract][Full Text] [Related]
27. Factors associated with malaria vaccine uptake in Sunyani Municipality, Ghana.
Tabiri D; Ouédraogo JCRP; Nortey PA
Malar J; 2021 Jul; 20(1):325. PubMed ID: 34315489
[TBL] [Abstract][Full Text] [Related]
28. [The RTS,S/AS01 malaria vaccine in children aged 5-17 months at first vaccination].
Vandoolaeghe P; Schuerman L
Pan Afr Med J; 2018; 30():142. PubMed ID: 30374388
[TBL] [Abstract][Full Text] [Related]
29. RTS,S/AS01 malaria vaccine-proven safe and effective?
Björkman A; Benn CS; Aaby P; Schapira A
Lancet Infect Dis; 2023 Aug; 23(8):e318-e322. PubMed ID: 37086747
[TBL] [Abstract][Full Text] [Related]
30. Determinants of willingness to accept child vaccination against malaria in Ghana.
Immurana M; Boachie MK; Klu D; Dalaba MA; Manyeh AK; Alhassan RK
Int J Health Plann Manage; 2022 May; 37(3):1439-1453. PubMed ID: 34984733
[TBL] [Abstract][Full Text] [Related]
31. Case reduction and cost-effectiveness of the RTS,S/AS01 malaria vaccine alongside bed nets in Lilongwe, Malawi.
Bell GJ; Loop M; Topazian HM; Hudgens M; Mvalo T; Juliano JJ; Kamthunzi P; Tegha G; Mofolo I; Hoffman I; Bailey JA; Emch M
Vaccine; 2020 May; 38(25):4079-4087. PubMed ID: 32362527
[TBL] [Abstract][Full Text] [Related]
32. Baseline incidence of meningitis, malaria, mortality and other health outcomes in infants and young sub-Saharan African children prior to the introduction of the RTS,S/AS01
RTS,S Epidemiology EPI-MAL-002 Study Group
Malar J; 2021 Apr; 20(1):197. PubMed ID: 33902599
[TBL] [Abstract][Full Text] [Related]
33. Community perceptions of malaria and vaccines in two districts of Mozambique.
Bingham A; Gaspar F; Lancaster K; Conjera J; Collymore Y; Ba-Nguz A
Malar J; 2012 Nov; 11():394. PubMed ID: 23186030
[TBL] [Abstract][Full Text] [Related]
34. Costing RTS,S introduction in Burkina Faso, Ghana, Kenya, Senegal, Tanzania, and Uganda: A generalizable approach drawing on publicly available data.
Galactionova K; Bertram M; Lauer J; Tediosi F
Vaccine; 2015 Nov; 33(48):6710-8. PubMed ID: 26518406
[TBL] [Abstract][Full Text] [Related]
35. Caregivers' perception and acceptance of malaria vaccine for Children.
Bam V; Mohammed A; Kusi-Amponsah A; Armah J; Lomotey AY; Budu HI; Atta Poku C; Kyei-Dompim J; Dwumfour C
PLoS One; 2023; 18(7):e0288686. PubMed ID: 37494408
[TBL] [Abstract][Full Text] [Related]
36. Challenges and perceptions of implementing mass testing, treatment and tracking in malaria control: a qualitative study in Pakro sub-district of Ghana.
Ndong IC; Okyere D; Enos JY; Amambua-Ngwa A; Merle CSC; Nyarko A; Koram KA; Ahorlu CS
BMC Public Health; 2019 Jun; 19(1):695. PubMed ID: 31170964
[TBL] [Abstract][Full Text] [Related]
37. The RTS,S/AS01 malaria vaccine in children 5 to 17 months of age at first vaccination.
Vandoolaeghe P; Schuerman L
Expert Rev Vaccines; 2016 Dec; 15(12):1481-1493. PubMed ID: 27841689
[TBL] [Abstract][Full Text] [Related]
38. Acceptance of and Adherence to a Four-Dose RTS,S/AS01 Schedule: Findings from a Longitudinal Qualitative Evaluation Study for the Malaria Vaccine Implementation Programme.
Price J; Gurley N; Gyapong M; Ansah EK; Awusabo-Asare K; Gyasi SF; Nkhoma P; Nyondo-Mipando AL; Okello G; Webster J; Desmond N; Hill J; Gordon WS
Vaccines (Basel); 2023 Dec; 11(12):. PubMed ID: 38140205
[TBL] [Abstract][Full Text] [Related]
39. [Vaccination against malaria].
Mura M
Med Trop Sante Int; 2023 Jun; 3(2):. PubMed ID: 37525687
[TBL] [Abstract][Full Text] [Related]
40. Potential public health impact of RTS,S malaria candidate vaccine in sub-Saharan Africa: a modelling study.
Sauboin CJ; Van Bellinghen LA; Van De Velde N; Van Vlaenderen I
Malar J; 2015 Dec; 14():524. PubMed ID: 26702637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
